Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVT201 in healthy volunteers and PBC/PSC patients
NCT06798454Phase 1Completed
- Sponsor
- Parvus Therapeutics
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Peptides, Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in primary biliary cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) comparing PVT201 with Placebo (2 arms). Primary endpoint: Adverse Events at 7 days. Started Oct 2024; status: completed.
02
Drugs
PVT201
03
Conditions
primary biliary cholangitis (PBC)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06798454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798454.